Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. Show More...

  • Website https://www.kintara.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 6.30 USD
  • Last Updated 18-10-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2011-06 2012-06 2013-12 2015-06 2016-06 2017-06 2018-06 2019-06 2020-06 2021-06 TTM
    Earnings Per Share USD -11.2 -4.6 -8.3 -7.4 -5.42 -3.16 -0.87 -1.6 -0.61
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 1.0 1.0 1.0 2.0 3.0 10.0 26.0 36.0
    Book Value Per Share * USD 0.95 -0.95 -3.61 0.54 -1.27 -0.09 -0.11 0.02
    Free Cash Flow Per Share * USD -4.34 -4.16 -5.4 -5.8 -2.93 -0.86 -0.81
    Return on Assets % -119.94 -302.43 -383.59 -126.56 -198.51 -124.38 -151.0 -146.3 -261.91 -503.65 -145.02
    Financial Leverage (Average) 11.04 51.67 13.62
    Return on Equity % -121.37 -861.17
    Return on Invested Capital % -121.37 -860.86
    Interest Coverage
    Current Ratio 0.18 17.31 3.02 10.07 6.03 4.3 1.94 1.07 4.24 4.36
    Quick Ratio 0.18 16.63 2.09 9.84 5.1 3.67 1.81 0.9 3.79 4.09
    Debt/Equity